Blar i Department of Clinical Science på tidsskrift "International Journal of Cancer"

Viser treff 1-5 av 5

    • Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts 

      Osterlund, Emerik; Ristimäki, Ari; Mäkinen, Markus J.; Kytölä, Soili; Kononen, Juha; Pfeiffer, Per; Soveri, Leena-Maija; Keinänen, Mauri; Sorbye, Halfdan; Nunes, Luís; Salminen, Tapio; Nieminen, Lasse; Uutela, Aki; Halonen, Päivi; Ålgars, Annika; Sundström, Jari; Kallio, Raija; Ristamäki, Raija; Lamminmäki, Annamarja; Stedt, Hanna; Heervä, Eetu; Kuopio, Teijo; Sjöblom, Tobias; Isoniemi, Helena; Glimelius, Bengt; Osterlund, Pia (Journal article; Peer reviewed, 2023)
      BRAF-V600E mutation (mt) is a strong negative prognostic and predictive biomarker in metastatic colorectal cancer (mCRC). Non-V600Emt, designated atypical BRAFmt (aBRAFmt) are rare, and little is known about their frequency, ...

    • Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer 

      Nakken, Sigve; Saveliev, Vladislav; Hofmann, Oliver; Møller, Pål; Myklebost, Ola; Hovig, Eivind (Journal article; Peer reviewed, 2021)
      The value of high-throughput germline genetic testing is increasingly recognized inclinical cancer care. Disease-associated germline variants in cancer patients areimportant for risk management and surveillance, surgical ...

    • Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer 

      Hamfjord, Julian; Guren, Tormod Kyrre; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per; Dajani, Olav; Lingjærde, Ole Christian; Tveit, Magne Kjell; Pallisgaard, Niels; Spindler, Karen-Lise Garm; Kure, Elin Wenche Hegland (Journal article; Peer reviewed, 2021)
      Detection of tumour-specific circulating cell-free DNA in plasma (ctDNA) fails in a significant number of cases depending on the clinical context. The primary aim was to investigate clinicopathological factors associated ...

    • Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon 

      Gansmo, Liv Beathe; Knappskog, Stian; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars; Lønning, Per Eystein (Peer reviewed; Journal article, 2015-07)
      MDM2 is a key regulator of the p53 tumor suppressor protein and is overexpressed in many human cancers. Two single nucleotide polymorphisms (SNPs) located in the MDM2 intronic promoter (P2) have been found to exert biological ...

    • Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up 

      Aamdal, Elin; Jacobsen, Kari Dolven; Straume, Oddbjørn; Kersten, Christian; Herlofsen, Oluf; Karlsen, Jarle; Hussain, Israr; Amundsen, Anita; Dalhaug, Astrid; Nyakas, Marta Sølvi; Schuster, Cornelia; Hagene, Kirsten Thorin; Holmsen, Kjersti; Russnes, Hege Elisabeth Giercksky; Skovlund, Eva; Kaasa, Stein; Aamdal, Steinar; Kyte, Jon A.; Guren, Tormod Kyrre (Journal article; Peer reviewed, 2022)
      Ipilimumab was the first treatment that improved survival in advanced melanoma. Efficacy and toxicity in a real-world setting may differ from clinical trials, due to more liberal eligibility criteria and less intensive ...